Table 2.
Basic characteristics of research.
| study | type | regions | treatment regiments | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| group1 | sample | group2 | sample | group3 | sample | group4 | sample | |||
| Lertkhachonsuk A 2009 (10) | RCT | Thailand | 1 | 22 | 2 | 27 | ||||
| Lee YJ 2017 (11) | retrospective study | Korea | 2 | 53 | 3 | 18 | 1 | 5 | ||
| Matsui H 1998 (12) | retrospective study | Japan | 4 | 192 | 5 | 126 | 1 | 46 | 2 | 36 |
| Baptista AM 2012 (13) | prospective study | Brazil | 2 | 20 | 1 | 20 | 1 | 20 | ||
| Gilani MM 2005 (14) | RCT | Iran | 3 | 18 | 6 | 28 | ||||
| Mu X 2018 (15) | retrospective study | China | 3 | 34 | 1 | 26 | ||||
| Mousavi A 2012 (16) | RCT | Iran | 3 | 50 | 4 | 25 | ||||
| Shahbazian N 2014 (17) | RCT | Iran | 3 | 15 | 6 | 15 | ||||
| Korkmaz V 2022 (18) | retrospective study | Turkey | 2 | 53 | 6 | 20 | ||||
| Maestá I 2018 (19) | retrospective study | Brazil | 2 | 151 | 6 | 174 | ||||
| Kang HL 2019 (20) | RCT | China | 1 | 49 | 4 | 59 | ||||
| Yarandi F 2016 (21) | RCT | USA | 4 | 32 | 3 | 30 | ||||
| Schorge JO 2003 (22) | prospective study | USA | 2 | 5 | 4 | 20 | 6 | 7 | ||
| Osborne RJ 2011 (23) | RCT | Canada | 6 | 107 | 3 | 109 | ||||
| Yarandi F 2008 (24) | RCT | Iran | 6 | 81 | 3 | 50 | ||||
| Hoskins PJ 2020 (25) | retrospective study | Canada | 3 | 100 | 6 | 97 | ||||
| Abrão RA 2008 (26) | retrospective study | Brazil | 1 | 42 | 4 | 42 | ||||
| Uberti EMH 2015 (27) | retrospective study | Brazil | 2 | 115 | 3 | 79 | ||||
| Roberts JP 1996 (28) | retrospective study | USA | 1 | 4 | 4 | 61 | ||||
| Kang WD 2010 (29) | retrospective study | Korea | 2 | 59 | 6 | 48 | ||||
| Matsui H 2005 (30) | retrospective study | Japan | 2 | 24 | 4 | 132 | 5 | 90 | 1 | 25 |
| Fülöp V 2021 (31) | retrospective study | Hungary | 2 | 304 | 1 | 109 | ||||
| Xu J 2022 (32) | retrospective study | China | 1 | 88 | 4 | 122 | ||||
| Anfinan N.M 2020 (33) | RCT | Jeddah | 2 | 26 | 6 | 34 | ||||
group: 1. ACT-D: 10 Kg/kg per day intravenously for 5 days, every 2 weeks, 2. MTX: 1 mg/kg per day on days 1, 3, 5, and 7, alternating with intramuscular folinic acid 0.1 mg/kg per day on days 2, 4, 6, and 8, every two weeks, 3. ACT-D: pulse actinomycin-D (1.25 mg/m2 ) once every 14 days with a maximum dose of 2 mg, 4. MTX: 0.4mg/kg 5 days, 5. VP-16: 2.0mg/kg 5 days, 6. MTX: 30 -50 mg/m2 weekly.